Company Overview and News
MDC Partners to Present at the 46th Annual J.P. Morgan Global Technology, Media and Communications Conference
The US Dollar Index rose ~0.7% to 93.2 on May 15—the highest level since December 26, 2017. June WTI oil futures increased ~0.5% on May 15. The strong US Dollar Index restricted the upside for oil prices during this period.
Ultra Petroleum Corp. (UPL - Free Report) was a big mover last session, as the company saw its shares rise more than 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 36.7% in the past one-month time frame.
May 15, 2018: Here are four stocks trading with heavy volume among 97 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by about 1.94 to 1 and on the Nasdaq, decliners led advancers by about 1.12 to 1.
Investors in Ultra Petroleum Corp. (UPL - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 18, 2018 $5 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
May 11, 2018: Here are four stocks trading with heavy volume among 67 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 1.12 to 1 and on the Nasdaq, advancers led decliners by about 1.13 to 1.
Good day, everyone, and welcome to today's Ultra Petroleum Corp. First Quarter 2018 Earnings Conference Call. [Operator Instructions]. Please note this call is being recorded.
May 10, 2018: Here are four stocks trading with heavy volume among 56 equities making new 52-week lows in Thursday’s session. On the NYSE advancers led decliners by about 2.34 to 1 and on the Nasdaq, advancers led decliners by about 1.5 to 1.
* ULTRA PETROLEUM ANNOUNCES FIRST QUARTER 2018 RESULTS, PROVIDES UPDATE ON HORIZONTAL PROGRAM & DEVELOPMENT PLAN
Houston, Texas, May 10, 2018 (GLOBE NEWSWIRE) -- Ultra Petroleum Corp. (NASDAQ: UPL) announces the following Webcast to discuss its first quarter 2018 financial and operating results:
HOUSTON, May 10, 2018 (GLOBE NEWSWIRE) -- Ultra Petroleum Corp. (NASDAQ:UPL) announces financial and operating results for the quarter ended March 31, 2018.
American International Group, Inc. (AIG - Free Report) is a provider of insurance products for customers. The Zacks Consensus Estimate for its current year earnings has been revised 2.9% downward over the last 30 days.
Ultra Petroleum Corp. (UPL - Free Report) recently provided first-quarter 2018 production update along with information regarding its borrowing base credit facility, which is supported by a lender consortium. The company plummeted 8.6% yesterday following the update, which brings it 32% down in the past 30-day period.
* ULTRA PETROLEUM ANNOUNCES FIRST QUARTER PRODUCTION ABOVE MID-POINT OF GUIDANCE, BORROWING BASE REAFFIRMED AT $1.4 BILLION AND CREDIT AGREEMENT AMENDMENT STEPPING UP LEVERAGE RATIO COVENANT TO 4.5X
During the first quarter of 2018, the Company’s production averaged 803 million cubic feet equivalent (MMcfe) per day, exceeding the mid-point of guidance of 790 to 810 MMcfe/d. Production volumes include 68.2 billion cubic feet of natural gas and 677.8 thousand barrels of oil and condensate and represents a 13% increase over the production volumes of first quarter 2017.
22h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
22h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET